Exendin-4 and peptide YY3-36NH2 synergistically reduce food intake through different mechanisms.
Published: 2005
Language: eng
Number of pages: 97
Description: Peripheral glucagon-like peptide-17-36NH2 (GLP-1) or peptide YY3-36NH2 (PYY3-36NH2) decreases food intake (FI) through unknown mechanisms. Male C57BL/6 mice were injected (i.p.) with exendin-41-39  (Ex4: GLP-1-receptor agonist) and/or PYY3-36NH2 (0.03--3 mug), and FI was determined over 24 h. Ex4 and PYY3-36NH2 alone decreased FI by up to 83 and 26%, respectively (P&lt;0.05-0.001), while the combination (0.06 mug plus 3 mug, respectively) synergistically reduced FI over 8 h (P&lt;0.05-0.001). Ex4 and/or PYY3-36NH2 delayed gastric emptying by 19% (P&lt;0.01-0.001) but had no effect on locomotion or taste. Sensory afferent ablation with capsaicin prevented the effects of Ex4 (P&lt;0.05), but had no effect on PYY3-36NH2-induced satiety. Exendin-4 9-39 (GLP-1-receptor antagonist) only abolished Ex4-induced anorexia (P&lt;0.05), whereas BIIE0246 (Y2-receptor antagonist) solely blocked the effects of PYY3-36NH2 (P&lt;0.001). Thus, Ex4 and PYY 3-36NH2 suppress FI via independent mechanisms. Therefore, administration of Ex4 together with PYY3-36NH2 may increase the suppression of FI without inducing significant side effects.
Notes: Source: Masters Abstracts International, Volume: 44-02, page: 0766.

Thesis (M.Sc.)--University of Toronto, 2005.

Electronic version licensed for access by U. of T. users.

GERSTEIN MICROTEXT copy on microfiche (2 microfiches).